Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Centre of Evolution and Cancer, The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK; and at The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
Gerhardt
G
Attard
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, Maryland 21231, USA.
Emmanuel S
ES
Antonarakis
D000736:Androstenes / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D011944:Receptors, Androgen / Q000235:genetics* / Q000378:metabolism
D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; C540278:enzalutamide; C089740:abiraterone